Zifa-01 is under clinical development by Tianjin Pharmaceuticals Group and currently in Phase II for Deep Vein Thrombosis (DVT). According to GlobalData, Phase II drugs for Deep Vein Thrombosis (DVT) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zifa-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zifa-01 overview

Zifa-01 is under development for the treatment of deep vein thrombosis and pulmonary embolism. The therapeutic candidate is formulated as tablet and administered through oral route.

Tianjin Pharmaceuticals Group overview

Tianjin Pharmaceutical Group is a state-owned, large-scale, comprehensive pharmaceutical company with four primary business segments: chemical and biopharmaceutical, green Chinese medicine, high-end medical equipment, and contemporary commercial logistics. The company is headquartered in Tianjing, Tianjin, China.

For a complete picture of Zifa-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.